Berotralstat-D4

Berotralstat-D4 is a medication used for the treatment of hereditary angioedema (HAE). HAE is a rare genetic condition that causes recurrent episodes of swelling in various parts of the body. Berotralstat-D4 works by inhibiting the activity of plasma kallikrein, an enzyme that plays a key role in the production of bradykinin, a molecule that causes the swelling associated with HAE. Berotralstat-D4 is a modified version of berotralstat, a drug that was previously approved for the treatment of HAE. The "D4" in the name refers to the fact that the medication contains four deuterium atoms, which are heavier versions of hydrogen atoms. These deuterium atoms help to slow down the breakdown of the drug in the body, making it more effective and longer-lasting. The chemical name of Berotralstat-D4 is (S)-2-(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)phenyl) propanoic acid-d4. Its chemical formula is C18H11D4N2O3, and its molecular weight is 325.41 g/mol. Berotralstat-D4 is taken orally in the form of a tablet. The recommended dosage is 150 mg once daily. The medication should be taken with food to increase its absorption. Berotralstat-D4 can cause side effects, such as nausea, diarrhea, headache, and upper respiratory tract infection. It is important to consult a healthcare provider before starting or stopping any medication.